Cell Therapeutics announces latest trial results for Zevalin

01/22/2009 | RTT News

Patients with mucosa-associated lymphoid tissue lymphoma and low-grade follicular lymphoma in conjunctiva exhibited an 83% complete response rate to Zevalin, Cell Therapeutics' radioimmunotherapy, during a front-line study. The results show that Zevalin could be a good alternative to current treatments, providing lower ocular toxicity and equal or better disease control, said the company's chief medical officer.

View Full Article in:

RTT News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Claims Director
PacificSource
Springfield, OR
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA